Your browser is no longer supported. Please, upgrade your browser.
TECH Bio-Techne Corporation weekly Stock Chart
TECH [NASD]
Bio-Techne Corporation
Index- P/E45.84 EPS (ttm)5.80 Insider Own0.50% Shs Outstand38.30M Perf Week-3.42%
Market Cap10.19B Forward P/E43.10 EPS next Y6.17 Insider Trans-33.78% Shs Float38.03M Perf Month-4.19%
Income229.30M PEG6.55 EPS next Q1.09 Inst Own97.30% Short Float1.49% Perf Quarter-1.75%
Sales738.70M P/S13.79 EPS this Y1.10% Inst Trans-0.30% Short Ratio2.43 Perf Half Y32.18%
Book/sh33.71 P/B7.88 EPS next Y17.09% ROA10.00% Target Price291.13 Perf Year35.82%
Cash/sh6.81 P/C39.02 EPS next 5Y7.00% ROE15.80% 52W Range155.17 - 286.68 Perf YTD21.07%
Dividend1.28 P/FCF87.61 EPS past 5Y-3.80% ROI6.90% 52W High-7.30% Beta1.06
Dividend %0.48% Quick Ratio3.70 Sales past 5Y14.80% Gross Margin65.40% 52W Low71.27% ATR9.56
Employees2250 Current Ratio4.70 Sales Q/Q5.30% Oper. Margin21.30% RSI (14)44.72 Volatility4.56% 3.36%
OptionableYes Debt/Eq0.33 EPS Q/Q-19.60% Profit Margin26.40% Rel Volume0.43 Prev Close266.55
ShortableYes LT Debt/Eq0.32 EarningsAug 04 BMO Payout25.00% Avg Volume232.68K Price265.76
Recom2.10 SMA20-2.87% SMA500.27% SMA20018.02% Volume99,387 Change-0.30%
Jul-15-20Downgrade Stephens Overweight → Equal-Weight
May-27-20Downgrade Stifel Buy → Hold $245 → $260
May-14-20Initiated The Benchmark Company Buy $290
Jan-08-20Resumed Stephens Overweight $250
Jan-08-20Initiated Wells Fargo Equal Weight $230
Jan-07-20Initiated Citigroup Neutral $235
Nov-15-19Initiated Stifel Buy
Jul-02-19Upgrade Janney Neutral → Buy $200 → $270
Jan-14-19Upgrade Stephens Equal-Weight → Overweight
Oct-31-18Downgrade Craig Hallum Buy → Hold
Oct-17-18Initiated Goldman Neutral $190
Jun-15-18Initiated Argus Buy $185
Jul-13-17Initiated Wells Fargo Market Perform
Feb-09-17Initiated Citigroup Buy $115
Jan-18-17Initiated Deutsche Bank Buy $115
Nov-10-16Resumed Leerink Partners Outperform $122
Jan-21-15Reiterated Robert W. Baird Outperform $102 → $104
Sep-20-13Upgrade Robert W. Baird Neutral → Outperform $76 → $90
Jun-08-12Initiated William Blair Mkt Perform
Feb-01-12Downgrade Robert W. Baird Outperform → Neutral $81 → $71
Aug-06-20 06:00AM  
06:00AM  
Aug-04-20 03:31PM  
07:25AM  
07:20AM  
06:30AM  
06:30AM  
Aug-03-20 07:00AM  
07:00AM  
Jul-22-20 11:23AM  
Jul-21-20 07:09PM  
07:00AM  
Jul-20-20 07:00AM  
Jul-13-20 10:09AM  
07:00AM  
Jun-11-20 07:00AM  
Jun-09-20 02:09PM  
07:00AM  
Jun-08-20 12:51PM  
07:00AM  
Jun-04-20 10:20AM  
May-27-20 07:00AM  
May-26-20 03:00AM  
May-25-20 11:37AM  
May-20-20 08:12AM  
May-19-20 04:05PM  
May-18-20 06:00PM  
May-11-20 11:32AM  
May-07-20 10:35AM  
May-04-20 01:26PM  
Apr-30-20 08:30PM  
Apr-23-20 12:32PM  
Apr-16-20 07:00AM  
Apr-15-20 07:00AM  
Apr-14-20 11:40AM  
Apr-09-20 11:12AM  
Apr-08-20 07:00AM  
Apr-01-20 04:01PM  
Mar-30-20 07:00AM  
Mar-25-20 09:23AM  
Mar-23-20 12:26AM  
Mar-18-20 07:00AM  
Feb-24-20 07:00AM  
Feb-17-20 07:00AM  
Feb-10-20 02:39AM  
Feb-06-20 02:14PM  
Feb-05-20 07:00AM  
Feb-04-20 07:55AM  
07:00AM  
06:30AM  
06:30AM  
Jan-28-20 12:31PM  
Jan-21-20 08:30AM  
Jan-09-20 07:00AM  
Jan-07-20 07:00AM  
Jan-02-20 07:00AM  
Jan-01-20 11:40AM  
Dec-23-19 01:10PM  
Dec-21-19 07:21PM  
Dec-17-19 07:00AM  
Nov-26-19 12:48PM  
Nov-08-19 11:53AM  
Nov-07-19 07:00AM  
Nov-06-19 09:30AM  
07:00AM  
Nov-05-19 07:00AM  
Oct-31-19 12:38AM  
Oct-29-19 07:55AM  
07:32AM  
06:30AM  
06:30AM  
Oct-28-19 03:42PM  
07:00AM  
Oct-14-19 08:10PM  
Oct-10-19 02:23PM  
Oct-08-19 09:15AM  
Oct-07-19 09:15AM  
Oct-02-19 02:05PM  
Oct-01-19 03:50PM  
Sep-26-19 03:38PM  
Sep-16-19 09:15AM  
Aug-28-19 05:48PM  
Aug-27-19 06:07AM  
Aug-23-19 07:16AM  
Aug-20-19 09:15AM  
Aug-15-19 09:15AM  
08:22AM  
Aug-13-19 09:15AM  
Aug-10-19 02:50PM  
Aug-07-19 06:45AM  
Aug-06-19 06:23PM  
08:55AM  
06:30AM  
06:30AM  
Aug-05-19 01:36PM  
Aug-02-19 11:46AM  
09:26AM  
Aug-01-19 11:55AM  
Jul-31-19 11:14AM  
Jul-29-19 11:38AM  
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and T-Cell activation technologies. This segment also provides manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including Food and Drug Administration -regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for original equipment manufacturers and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays comprising the ExoDx Prostate test for prostate cancer diagnosis. This segment also manufactures and sells tissue-based in-situ hybridization assays for research and clinical use. Bio-Techne Corporation has partnership with Kantaro Biosciences to develop and scale production of COVID-19 serology test. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Furlow Brenda S.SVP - General CounselJul 09Option Exercise108.499,079984,98113,390Jul 13 04:02 PM
Furlow Brenda S.SVP - General CounselJul 09Sale275.769,0792,503,6524,311Jul 13 04:02 PM
Hippel JamesChief Financial OfficerJul 07Option Exercise108.492,577279,57911,884Jul 08 05:47 PM
Hippel JamesChief Financial OfficerJul 07Sale271.432,577699,4829,307Jul 08 05:47 PM
Hippel JamesChief Financial OfficerJul 06Option Exercise108.4921,5022,332,75230,809Jul 08 05:47 PM
Hippel JamesChief Financial OfficerJul 06Sale271.6121,5025,840,1529,307Jul 08 05:47 PM
Eansor Norman DavidPresident-Protein SciencesMay 29Option Exercise108.497,909858,0477,909Jun 01 05:58 PM
WIENS HAROLD JDirectorMay 29Option Exercise101.193,985403,2428,828Jun 02 05:13 PM
WIENS HAROLD JDirectorMay 29Sale260.003,9851,036,1004,843Jun 02 05:13 PM
Eansor Norman DavidPresident-Protein SciencesMay 29Sale262.007,9092,072,1400Jun 01 05:58 PM
Furlow Brenda S.SVP - General CounselMay 28Option Exercise105.517,595801,35810,306Jun 01 05:58 PM
Eansor Norman DavidPresident-Protein SciencesMay 28Option Exercise108.493,448374,0743,448Jun 01 05:58 PM
Eansor Norman DavidPresident-Protein SciencesMay 28Sale260.193,448897,1340Jun 01 05:58 PM
Furlow Brenda S.SVP - General CounselMay 28Sale260.145,9951,559,5334,311Jun 01 05:58 PM
Kummeth Charles R.Chief Executive OfficerMay 26Option Exercise86.2521,1591,824,964151,148May 28 05:41 PM
Eansor Norman DavidPresident-Protein SciencesMay 22Option Exercise104.0412,6001,310,93712,600May 26 05:13 PM
Eansor Norman DavidPresident-Protein SciencesMay 22Sale267.9312,6003,375,9260May 26 05:13 PM
Eansor Norman DavidPresident-Protein SciencesMay 21Option Exercise94.3511,0371,041,34111,037May 26 05:13 PM
BAUMGARTNER ROBERT VDirectorMay 21Option Exercise70.355,000351,75014,221May 26 05:13 PM
BAUMGARTNER ROBERT VDirectorMay 21Sale266.425,0001,332,1179,221May 26 05:13 PM
Eansor Norman DavidPresident-Protein SciencesMay 21Sale267.4911,0372,952,3160May 26 05:13 PM
WIENS HAROLD JDirectorMay 06Option Exercise87.344,260372,0689,481May 08 04:17 PM
WIENS HAROLD JDirectorMay 06Sale250.004,2601,065,0005,221May 08 04:17 PM
WIENS HAROLD JDirectorApr 30Option Exercise91.784,000367,1209,221May 04 04:35 PM
WIENS HAROLD JDirectorApr 30Sale225.004,000900,0005,221May 04 04:35 PM
Eansor Norman DavidPresident-Protein SciencesMar 04Sale198.681,387275,5690Mar 06 04:08 PM
HIGGINS JOHN LDirectorFeb 12Option Exercise61.465,000307,3009,021Feb 14 04:13 PM
HIGGINS JOHN LDirectorFeb 12Sale205.235,0001,026,1334,021Feb 14 04:13 PM
Kummeth Charles R.Chief Executive OfficerJan 06Option Exercise67.4610,276693,219140,265Jan 08 04:34 PM
Kummeth Charles R.Chief Executive OfficerJan 06Sale217.2810,2762,232,769129,989Jan 08 04:34 PM
Kummeth Charles R.Chief Executive OfficerJan 03Option Exercise67.467,999539,613137,988Jan 06 04:39 PM
Kummeth Charles R.Chief Executive OfficerJan 03Sale217.567,9991,740,240129,989Jan 06 04:39 PM
Kummeth Charles R.Chief Executive OfficerJan 02Option Exercise67.4619,8431,338,609149,832Jan 06 04:39 PM
Kummeth Charles R.Chief Executive OfficerJan 02Sale218.5919,8434,337,541129,989Jan 06 04:39 PM
Kummeth Charles R.Chief Executive OfficerDec 24Option Exercise67.4647131,774130,460Dec 27 04:31 PM
Kummeth Charles R.Chief Executive OfficerDec 24Sale222.18471104,648129,989Dec 27 04:31 PM
Kummeth Charles R.Chief Executive OfficerDec 23Option Exercise67.4665944,456130,648Dec 27 04:31 PM
Kummeth Charles R.Chief Executive OfficerDec 23Sale222.08659146,351129,989Dec 27 04:31 PM
Kummeth Charles R.Chief Executive OfficerDec 20Option Exercise67.465,767389,042135,756Dec 23 04:31 PM
Kummeth Charles R.Chief Executive OfficerDec 20Option Exercise67.465,767389,042135,756Dec 23 04:32 PM
Kummeth Charles R.Chief Executive OfficerDec 20Sale222.065,7671,280,632129,989Dec 23 04:32 PM
Kummeth Charles R.Chief Executive OfficerDec 20Sale222.065,7671,280,632129,989Dec 23 04:31 PM
Furlow Brenda S.SVP - General CounselDec 12Option Exercise94.358,000754,80010,711Dec 17 04:32 PM
Furlow Brenda S.SVP - General CounselDec 12Sale215.608,0001,724,7722,711Dec 17 04:32 PM
Kummeth Charles R.Chief Executive OfficerDec 10Option Exercise67.4670347,424136,459Dec 12 04:35 PM
Kummeth Charles R.Chief Executive OfficerDec 10Sale222.01703156,073135,756Dec 12 04:35 PM
WIENS HAROLD JDirectorDec 04Option Exercise87.832,000175,6607,221Dec 06 04:50 PM
WIENS HAROLD JDirectorDec 04Sale217.852,000435,6935,221Dec 06 04:50 PM
Kummeth Charles R.Chief Executive OfficerNov 29Sale222.6210022,262135,756Dec 02 04:22 PM
Kummeth Charles R.Chief Executive OfficerNov 27Option Exercise67.4611,772794,139147,628Dec 02 04:22 PM
Kummeth Charles R.Chief Executive OfficerNov 27Sale222.1211,7722,614,814135,856Dec 02 04:22 PM
Nusse RoelandDirectorNov 25Option Exercise60.7915,000911,90020,721Nov 29 11:35 AM
Nusse RoelandDirectorNov 25Sale219.338,3471,830,73112,374Nov 29 11:35 AM
Hippel JamesChief Financial OfficerNov 22Option Exercise94.3523,6512,231,47232,958Nov 25 04:25 PM
Hippel JamesChief Financial OfficerNov 22Sale215.5923,6515,098,9019,307Nov 25 04:25 PM
Hippel JamesChief Financial OfficerNov 21Option Exercise94.3511,3491,070,77820,656Nov 25 04:25 PM
Hippel JamesChief Financial OfficerNov 21Sale215.3611,3492,444,1329,307Nov 25 04:25 PM
Kummeth Charles R.Chief Executive OfficerSep 09Buy185.0020037,000100Sep 11 04:42 PM
Kummeth Charles R.Chief Executive OfficerAug 13Option Exercise67.467,410499,879110,877Aug 15 04:45 PM